Immunological Tolerance clinical trials at University of California Health
2 research studies open to eligible people
Immunological Tolerance in Patients With Mismatched Kidney Transplants
open to eligible people ages 18 years and up
This study seeks to determine if administration of the drug belumosudil (KD025) will be safe and improve transplant tolerance in subjects undergoing combined Human Leukocyte Antigen (HLA) single haplotype-matched related or 0-3 antigen (at A, B, C, DR) HLA mismatched unrelated living donor kidney and hematopoietic stem cell transplantation.
at UCLA
Retro-active Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-identical Kidney Transplants
open to eligible people ages 18 years and up
The study seeks to determine if patients with a pre-existing, well-functioning kidney transplant from a HLA-identical living donor can be withdrawn from immunosuppressive medications without compromising allograft function through hematopoietic stem cell (HPSC) infusion from the same donor. HPSC infusion will be preceded by a conditioning regimen of total lymphoid irradiation (TLI) and rabbit anti-thymocyte globulin (rATG).
at UCLA
Our lead scientists for Immunological Tolerance research studies include Neil Kogut, MD Jeffrey Veale, MD.
Last updated: